Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov 22:4:83.
doi: 10.1186/1477-7819-4-83.

Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer

Masayoshi Yasui  1 , Masataka Ikeda, Mitsugu Sekimoto, Hirofumi Yamamoto, Ichiro Takemasa, Takafumi Ueda, Junzo Shimizu, Mutsumi Fukunaga, Osamu Suzuki, Takehiro Inoue, Morito Monden
Affiliations

Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer

Masayoshi Yasui et al. World J Surg Oncol. .

Abstract

Background: Surgical attempts for locally recurrent rectal cancer often fail due to local re-recurrence and distant metastasis. Preoperative chemoradiation may enhance better local control and survival. The aim of this study was to assess the safety of oral uracil and tegafur (UFT) plus leucovorin (LV), and irinotecan combined with radiation and determine the maximum-tolerated dose (MTD) and dose limiting toxicity (DLT) of the triple drug regimen.

Patients and methods: Patients with locally recurrent rectal cancer received escalating doses of irinotecan on days 1, 8, 15, and 22 (starting at 30 mg/m2, with 10 mg increments between consecutive cohorts) and fixed doses of UFT (300 mg/m2) plus LV (75 mg/day) on days 3 to 7, 10 to 14, 17 to 21, and 24 to 28. Radiation was given 5 days per week totaling 40 to 50 Gy (2Gy/day).

Results: Six patients were treated at the starting dose, and 2 received the full scheduled chemoradiotherapy. The other 4 patients had grade 3 diarrhea and diarrhea was the DLT. One patient had partial response and he had subsequently radical surgical resection. Median progression free survival for local recurrence was 320 days.

Conclusion: Irinotecan plus UFT/LV with concomitant radiotherapy in patients with locally recurrent rectal cancer was not feasible due to diarrhea in this setting. Modification of the treatment is needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schema of treatment regimen.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McDermott FT, Hughes ES, Pihl E, Johnson WR, Price AB. Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients. Br J Surg. 1985;72:34–37. - PubMed
    1. Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg. 1996;83:293–304. - PubMed
    1. Bozzetti F, Bertario L, Rossetti C, Gennari L, Andreola S, Baratti D, Gronchi A. Surgical treatment of locally recurrent rectal carcinoma. Dis Colon Rectum. 1997;40:1421–1424. doi: 10.1007/BF02070705. - DOI - PubMed
    1. Wanebo HJ, Antoniuk P, Koness RJ, Levy A, Vezeridis M, Cohen SI, Wrobleski DE. Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum. 1999;42:1438–1448. doi: 10.1007/BF02235044. - DOI - PubMed
    1. Maetani S, Nishikawa T, Iijima Y, Tobe T, Kotoura Y, Shikata J, Yamamura T. Extensive en bloc resection of regionally recurrent carcinoma of the rectum. Cancer. 1992;69:2876–2883. doi: 10.1002/1097-0142(19920615)69:12<2876::AID-CNCR2820691203>3.0.CO;2-Q. - DOI - PubMed

LinkOut - more resources